secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-013897
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Chief Medical Officer Toby Ferguson resigns; CEO Sandrock takes over clinical leadership
--------------------------------------------------------------------------------

- Toby Ferguson, M.D., Ph.D., resigned as CMO effective Feb 20, 2026, to pursue a new opportunity.
- Resignation is not due to any disagreement with the company.
- CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will assume interim oversight of clinical development programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926013897/0001104659-26-013897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926013897/tm266042d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer